InvestorsObserver
×
News Home

Ibio Inc (IBIO) Increases 2.37% After Announcing Encouraging Pre-Clinical COVID-19 Vaccine Results

Monday, August 10, 2020 11:20 AM | Nick Dey

Mentioned in this article

Ibio Inc (IBIO) Increases 2.37% After Announcing Encouraging Pre-Clinical COVID-19 Vaccine Results

Ibio Inc (IBIO) is trading up 2.37% at $3.89 per share so far Monday. IBIO is up after announcing encouraging pre-clinical data for the company’s COVID-19 vaccine candidate. Early tests for the vaccine candidate showed an increase in anti-SARS-CoV-2 spike tiers were observed 21-days after immunization, with titers continuing to increase through the longevity of the 42-day study.

Ibio Inc (IBIO) stock is higher by 480.60% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives IBIO stock a score of 45 out of a possible 100.

That score is chiefly influenced by a fundamental score of 0. In addition to the average rating from Wall Street analysts, IBIO stock has a mean target price of 2.55. This means analysts expect the stock to fall 34.45% over the next 12 months. IBIO’s score also includes a short-term technical score of 40. The long-term technical score for IBIO is 94.

What’s Happening with IBIO Stock Today

Ibio Inc (IBIO) stock has gained 2.37% while the S&P 500 is down -0.29% as of 11:05 AM on Monday, Aug 10. IBIO is higher by $0.09 from the previous closing price of $3.80 on volume of 25,991,681 shares. Over the past year the S&P 500 has risen 15.91% while IBIO is higher by 480.60%. IBIO lost -$1.18 per share in the over the last 12 months.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App